News for hackers. Stuff that matters.
Re:Cells edited using CRISPR–Cas9 injected into a person for... by nonbel on Tuesday November 15, 2016 @07:46PM (#12963680)
That seems to be the favorite interpretation. We need to see what data they present that favors it (ie % survival of the treated cells, number of initial cells, % mutants at that location detected in control cells). Also, this is kind of weird, because they say it is non-randomized:

  Study Design: 	
  Allocation: Non-Randomized
  Endpoint Classification: Safety Study
  Intervention Model: Parallel Assignment
  Masking: Open Label
  Primary Purpose: Treatment
But later it says:

  Progression free survival - PFS [ Time Frame: From date of randomization until 
  the date of first documented progression or date of death from any cause, whichever
  came first, assessed up to average 10 months ] [ Designated as safety issue: No ]

  Overall Survival - OS [ Time Frame: The time from randomization to death from any
  cause, assessed up to 2 years ] [ Designated as safety issue: No ]
So is the treatment randomized or not? The info on that site may not be reliable... maybe it makes sense somehow though.
Re:Cells edited using CRISPR–Cas9 injected into a person for... by ejstronge on Tuesday November 15, 2016 @07:59PM (#12963732)
I would be surprised if this safety trial were randomized with respect to the CRISPR manipulation. I agree with your assessment of needing more data to believe that the gene editing manipulation was successful.

I suspect the randomization relates to the allocation to the experimental arms as described on the reporting page:

    This is a dose-escalation study of ex-vivo knocked-out, 
    expanded, and selected PD-1 knockout-T cells from 
    autologous origin. Patients are assigned to 1 of 3  
    treatment groups to determine the maximal tolerant dose
Re:Cells edited using CRISPR–Cas9 injected into a person for... by nonbel on Wednesday November 16, 2016 @09:39AM (#12967173)
Nice catch, why do you think a safety trial should not use randomized allocation of the treatment (but it does make sense for dose) though?